Correction: Proteomic-based stratification of intermediate-risk prostate cancer patients

Key Points

• The aim is to determine if a protein-based signature can effectively stratify intermediate-risk prostate cancer patients' risk of recurrence.
• Utilized proteomic analysis to identify protein signatures in prostate cancer patients.
• Focused on patients with Gleason grade groups 2 and 3.
• Employed statistical methods to assess the predictive power of the identified protein signatures.
• Identified a specific protein signature linked to the risk of biochemical recurrence.
• The signature demonstrated a strong ability to differentiate between low and high-risk patients.